The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
- Study ID
- NCT01564108
- Phase
- PHASE2
- Status
- Completed
Conditions
- Steroid-induced Glaucoma - Borderline
- Uveitis Related Cystoid Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — DRUGSeries of intravitreal injections of Ranibizumab
Study Details
Anti-vascular endothelial growth factor (VEGF) treatments show great promise in the treatment of a variety of retinal diseases. This study addresses a condition which affects a large number of our patients in whom the investigators face difficult management decisions. These patients with uveitis are severely disabled with visual loss related to cystoid macular oedema (CMO) and few options remain when standard treatment has either failed or is contraindicated. The concentration of VEGF is increased in the eyes of patients with uveitis. Our hypothesis is that a series of injections of Ranibizumab may be an effective treatment for CMO. It is hoped that anti-VEGF therapy will have fewer side-effects than existing therapies and will be more effective in improving quality of life by reducing macular thickening and restoring visual function.
Key Dates
- First listed
- Mar 27, 2012
- Start date
- May 1, 2012
- Status verified
- Mar 2019
- Primary completion
- Jun 30, 2014
- Completion
- Jun 30, 2014
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: RanibizumabSeries of intravitreal injections of Ranibizumab
Primary Outcome Measure
The number of patients in whom, by consensus, no further treatment is required. [ Time Frame: Data will be collected at every patient visit which will take place every 4-5 weeks, and analysed at 12 months follow-up ]